Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement
- 1 May 2002
- journal article
- letter
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 8 (5), 423-425
- https://doi.org/10.1038/nm0502-423
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Adenosine Deaminase Deficiency: Genotype-Phenotype Correlations Based on Expressed Activity of 29 Mutant AllelesAmerican Journal of Human Genetics, 1998
- T lymphocytes with a normal ADA gene accumulate after transplantation of transduced autologous umbilical cord blood CD34+ cells in ADA-deficient SCID neonatesNature Medicine, 1998
- Successful Peripheral T-Lymphocyte–Directed Gene Transfer for a Patient With Severe Combined Immune Deficiency Caused by Adenosine Deaminase DeficiencyBlood, 1998
- T Lymphocyte-Directed Gene Therapy for ADA − SCID: Initial Trial Results After 4 YearsScience, 1995
- Gene Therapy in Peripheral Blood Lymphocytes and Bone Marrow for ADA − Immunodeficient PatientsScience, 1995
- Engraftment of gene–modified umbilical cord blood cells in neonates with adenosine deaminase deficiencyNature Medicine, 1995
- Transfer of the ADA Gene into Bone Marrow Cells and Peripheral Blood Lymphocytes for the Treatment of Patients Affected by ADA-Deficient SCIDHuman Gene Therapy, 1993
- Antibody responses to bacteriophage phi X174 in patients with adenosine deaminase deficiencyBlood, 1992
- Bone marrow transplantation only partially restores purine metabolites to normal in adenosine deaminase-deficient patients.JCI Insight, 1981
- Severe Combined Immunodeficiency and Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1975